ROIV Stock Roivant Sciences Ltd.
US · NasdaqGSLast in our picks 2026-10-07 — not in the current list; analysis below is from that screen
Pipeline optionality and repeated target increases support speculative upside potential.
Future value: $48.08 (+35.33%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Guggenheim raised target twice and maintained Buy.
- ▾Below 50-day MA (-2.97%)
- ▸Above 200-day MA — long-term uptrend
- ▸~35% upside to price target
Is ROIV a buy right now?
Trend: ROIV is trading below the 50-day average (-1.61%), RSI 51 — neutral momentum, with a 3-month return of +6.53%.
Valuation & quality: Roivant Sciences Ltd. trades on forward P/E -21.0, price-to-book 6.16; fundamentals show net margin 0.0%, return on equity -8.5%, revenue growth -33.5% year on year.
Analyst consensus: 11 analysts have a mean 12-month price target of $48.91 (+35.7% vs the last close; range $41.00 – $62.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 4) — Pipeline optionality and repeated target increases support speculative upside potential.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -4.30% | +3.00% | +5.10% | +18.00% | -4.20% | +2.20% | +5.60% | -1.40% |
Fundamentals
Analyst price target
Technical signals
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Sector: Healthcare · Industry: Biotechnology · United Kingdom · 721 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.